Novo Nordisk delivered 15% sales growth and 10% operating profit growth (constant FX) for the first nine months of 2025, but narrowed full-year guidance to 8-11% sales and 4-7% operating profit due to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results